Dr. Andrei Iagaru, MD
Claim this profileStanford University, School of Medicine
Studies Adenocarcinoma
Studies Prostate Cancer
14 reported clinical trials
20 drugs studied
Area of expertise
1Adenocarcinoma
Stage III
Stage IV
2Prostate Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Andrei Iagaru, MD is currently running
[225Ac]-FPI-2068
for Cancer
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).
Recruiting1 award Phase 16 criteria
18F Fluorocholine PET/CT
for Parathyroid Tumors
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Recruiting1 award Phase 2 & 3
More about Andrei Iagaru, MD
Clinical Trial Related7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Andrei Iagaru, MD has experience with
- Gallium Ga 68-labeled GRPR Antagonist BAY86-7548
- [18F]FP-R01-MG-F2
- Fluorine F 18 DCFPyL PET/CT
- 68Ga-RM2
- Gallium Ga 68 DOTA-NeoBOMB1
- Gallium Ga 68 PSMA-R2
Breakdown of trials Andrei Iagaru, MD has run
Adenocarcinoma
Prostate Cancer
- 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
- F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
- Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Prostate Adenocarcinoma
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrei Iagaru, MD specialize in?
Andrei Iagaru, MD focuses on Adenocarcinoma and Prostate Cancer. In particular, much of their work with Adenocarcinoma has involved Stage III patients, or patients who are Stage IV.
Is Andrei Iagaru, MD currently recruiting for clinical trials?
Yes, Andrei Iagaru, MD is currently recruiting for 6 clinical trials in Palo Alto California. If you're interested in participating, you should apply.
Are there any treatments that Andrei Iagaru, MD has studied deeply?
Yes, Andrei Iagaru, MD has studied treatments such as Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, [18F]FP-R01-MG-F2, Fluorine F 18 DCFPyL PET/CT.
What is the best way to schedule an appointment with Andrei Iagaru, MD?
Apply for one of the trials that Andrei Iagaru, MD is conducting.
What is the office address of Andrei Iagaru, MD?
The office of Andrei Iagaru, MD is located at: Stanford University, School of Medicine, Palo Alto, California 94304 United States. This is the address for their practice at the Stanford University, School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.